The detection of BRAF V600E SNV in cfDNA released by living, dying, or dead tumor cells using patient plasma or serum has also been associated with tumor burden, minimal residual disease, treatment response, and clonal evolution [71]. This evidence concerns the gene BRAF and neoplasm.